Drug intelligence / Profile preview

methylphenidate + omega-3

Development stage: Unknown
Lead developer: Novartis
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Methylphenidate + omega-3 is a combination therapy that pairs a central nervous system stimulant (methylphenidate) with omega-3 fatty acids for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). This combination has been studied for its potential to enhance therapeutic effects while reducing adverse events compared to methylphenidate alone. Research suggests that the combination may have tolerability benefits over methylphenidate monotherapy, though results on efficacy are mixed across studies.

Other names: MPH + Omega-3/6MPH + Omegamethylphenidate plus omega-3

Targets

SERT (Sodium-dependent serotonin transporter)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on methylphenidate + omega-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methylphenidate + omega-3.

Explore the full profile